MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

BIOLOGICAL6 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), VaxGen

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

CompletedNCT00002402

VaxGenHIV Infections

Target: 120Updated: 2005-06-24

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

CompletedNCT00000879

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity

End: 2005-04-30Target: 48Updated: 2021-10-29

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

CompletedNCT00000884

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2000-10-31Updated: 2021-10-29

Phase 2

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

CompletedNCT00007332

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2003-04-30Target: 330Updated: 2021-10-15

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

CompletedNCT00000871

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2000-01-31Target: 420Updated: 2021-11-04

Phase 3

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

CompletedNCT00002441

VaxGenHIV Infections, HIV Seronegativity

Target: 5000Updated: 2005-06-24

Related Papers

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.

2022-06-0134 citations